8-K: Clene Inc. Secures In-Person Meeting with FDA to Discuss CNM-Au8 for ALS

Clene Inc. has been granted an in-person meeting with the FDA to discuss its CNM-Au8 drug for ALS, following initial concerns about its briefing package.

Summary

• Clene Inc. announced it will have an in-person meeting with the FDA to discuss its CNM-Au8 drug for amyotrophic lateral sclerosis (ALS).
• The meeting will include key FDA personnel such as the Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 review team.
• The meeting will also include recognized key opinion leaders in ALS, biostatistics, and biomarkers.
• Initially, the FDA's Division of Neurology 1 (DN1) indicated that Clene's briefing package for CNM-Au8 was not sufficient for an NDA submission under the accelerated approval pathway.
• Following further dialogue, the FDA agreed to the in-person meeting to re-evaluate the submission.
• Clene has over 700 patient-years of safety data for CNM-Au8, with no significant safety concerns or trends identified.
• No serious adverse events have been linked to CNM-Au8 treatment by clinical trial investigators.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the in-person meeting with the FDA, which is a positive step after initial concerns. However, the initial rejection of the briefing package and the inherent risks in drug development temper the overall optimism.

Positives

• Clene has secured an in-person meeting with the FDA, indicating a willingness to reconsider their initial assessment of the CNM-Au8 data.
• The meeting will include key FDA decision-makers and external experts, providing a comprehensive review of the data.
• The extensive safety data for CNM-Au8, with over 700 patient-years and no significant safety concerns, is a positive sign.
• The absence of serious adverse events related to CNM-Au8 treatment is encouraging.

Negatives

• The FDA initially found Clene's briefing package for CNM-Au8 insufficient for an NDA submission under the accelerated approval pathway.
• This suggests that there are concerns about the data or the approach that need to be addressed in the upcoming meeting.

Risks

• The FDA may still not approve CNM-Au8 for accelerated approval after the in-person meeting.
• The company's ability to demonstrate the efficacy and safety of its drug candidates is not guaranteed.
• Clinical results may not support further development or marketing approval.
• Regulatory agencies may affect the initiation, timing, and progress of clinical trials and marketing approval.
• The company has a limited operating history and may face challenges in obtaining additional funding.

Future Outlook

The company anticipates a meeting with the FDA before the end of November 2024 to discuss CNM-Au8 development for ALS. The outcome of this meeting will be critical for the future of the drug's development and potential approval.

Management Comments

• Clene is appreciative of the FDA's use of process and regulatory flexibility to obtain the best outcome for people living with ALS.
• Clene looks forward to the opportunity to have experts present their views to the FDA and address questions on ALS biomarkers, related clinical endpoints, and survival data.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for ALS, a devastating neurodegenerative disease. The FDA's willingness to reconsider Clene's submission after initial concerns highlights the regulatory challenges in this field and the importance of ongoing dialogue between companies and regulatory bodies.

Comparison to Industry Standards

• The FDA's initial rejection of the briefing package is not uncommon in the pharmaceutical industry, especially for novel therapies targeting complex diseases like ALS.
• The subsequent agreement to an in-person meeting is a positive development, as it allows for a more detailed discussion of the data and potential pathways for approval.
• Other companies developing ALS treatments, such as Biogen with Tofersen and Amylyx Pharmaceuticals with Relyvrio, have also faced regulatory hurdles, highlighting the challenges in this space.
• Clene's 700 patient-years of safety data is a significant amount, and the lack of serious adverse events is a positive sign compared to some other experimental therapies.

Stakeholder Impact

• Shareholders may react positively to the news of the in-person meeting with the FDA, but the outcome of the meeting will be crucial.
• Patients with ALS and their families may have renewed hope for a potential treatment option.
• Employees of Clene may be encouraged by the progress in the development of CNM-Au8.
• The FDA's decision will impact the future of the company and its ability to bring CNM-Au8 to market.

Next Steps

• Clene will prepare for and attend the in-person meeting with the FDA before the end of November 2024.
• Clene will present its data on CNM-Au8, including biomarker, clinical endpoint, and survival data, to the FDA and key opinion leaders.
• Clene will address any questions and concerns raised by the FDA during the meeting.

Key Dates

Keywords

CNM-Au8, FDA, ALS, amyotrophic lateral sclerosis, biomarker, neurodegenerative diseases, clinical trial, accelerated approval, safety data, NDA